Lacidipine
Appearance
![]() | |
Clinical data | |
---|---|
Trade names | Lacipil, Motens |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ~10% |
Protein binding | >95% |
Metabolism | Hepatic |
Onset of action | 30–50 min |
Elimination half-life | 13–19 hours |
Excretion | Feces (~70%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.166.373 |
Chemical and physical data | |
Formula | C26H33NO6 |
Molar mass | 455.551 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Lacidipine (tradenames Lacipil or Motens) is a calcium channel blocker. It is available as tablets containing 2 or 4 mg.
It was patented in 1984 and approved for medical use in 1991.[1]
References
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 466. ISBN 9783527607495.
External links